Palantir shares slip by 7% despite posting record revenue in third quarter
Investing.com - UBS raised its price target on Insmed (NASDAQ:INSM) to $223.00 from $194.00 on Friday, maintaining a Buy rating as the stock jumped 13% following positive Brinsupri launch data. The stock currently trades at $191.53, having surged 21.65% over the past week and an impressive 181.32% year-to-date.
The biotech company reported 2,550 new patient starts for Brinsupri in the third quarter, exceeding investor expectations according to UBS analyst discussions with buyers.
UBS noted that Insmed has become a "consensus long" among investors, but suggested the stock still has room to grow as both buy-side and sell-side estimates for Brinsupri are likely to increase following the latest update. With a market cap of $40.3 billion and strong analyst consensus (1.26, where 1 is Strong Buy), the stock is trading near its 52-week high of $194.70. InvestingPro analysis indicates the stock may be overvalued based on its Fair Value assessment.
The investment bank also pointed out that current stock levels don’t fully price in pipeline opportunities, including potential in CRSsNP, HS for brenso, and TPIP indications. Despite not being profitable over the last twelve months, InvestingPro data shows Insmed operates with a moderate debt level and maintains strong liquidity with a current ratio of 6.68, indicating its liquid assets comfortably exceed short-term obligations.
Despite the strong third-quarter performance, Insmed management has adopted a cautious stance regarding fourth-quarter results, indicating that the upcoming quarter will provide a better indication of ongoing demand for Brinsupri. The company’s next earnings are expected on February 19, 2026. For deeper insights into Insmed’s financial health and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Insmed reported its third-quarter 2025 earnings, revealing a significant revenue beat. The company posted a revenue of $142 million, surpassing the expected $114.87 million. However, the earnings per share (EPS) were -$1.75, missing the forecast of -$1.34. Additionally, Insmed’s Brinsupri revenue for the quarter was $28.1 million, significantly exceeding both TD Cowen’s estimate of $10.5 million and the Street consensus of $7.2 million. This revenue included $16.8 million in net stocking. As a result of these developments, TD Cowen raised its price target for Insmed to $223, while maintaining a Buy rating on the stock. These recent developments have led to notable market reactions and adjustments in analyst evaluations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.